This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Sanofi is to buy the vaccines biotech Protein Sciences in a deal worth up to $750 million, after missing out on bigger acquisitions. The French drugmaker tried to buy cancer drugs firm Medivation ...

Before the Sanofi acquisition closes, Inhibrx will spin off its other drug assets, which target various cancers, into a company to be called New Inhibrx. That firm will have $200 million in cash ...

Crossmark Global Holdings Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 23.7% during the ...

He added that while there was no timeline for how long Sanofi would be involved in Opella, "we expect to be involved and in partnership for a long time". Opella employs 11,000 people globally and ...

The acquisition of INBRX-101 is seen as a step towards strengthening Sanofi’s rare disease business. Following the acquisition, New Inhibrx will continue to operate under the “Inhibrx” name ...